AvenCell Therapeutics

<cite index="3-5,5-6">AvenCell Therapeutics was founded in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics.</cite> <cite index="3-2">The company is building a cell therapy platform that targets difficult-to-treat cancers, with lead programs focusing on acute myeloid leukemia (AML) and B-cell malignancies, and additional programs targeting other hematological malignancies, auto-immune diseases, and solid tumors.</cite> <cite index="3-3">AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient.</cite> <cite index="14-8,14-9">The company's switchable or "universal" CAR-T platform uses engineered T cells with a universal receptor that is only activated when bound to a targeting module, allowing for on and off control of therapeutic activity.</cite> <cite index="8-16">The company is currently active as a private company.</cite>